Detail akcie Edwards Lifesci online

Business Summary: Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Edwards Lifesciences Corp revenues increased 17% to $1.65B. Net income before extraordinary items increased 4% to $380.7M. Revenues reflect Europe segment increase of 29% to $442.6M, United States segment increase of 12% to $937.6M. Net income was partially offset by selling and general administrative other increase of 12% to $496.3M (expense).